Modality
Fusion Protein
MOA
BETi
Target
CD20
Pathway
Proteasome
SMACFMCC
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
~May 2020
→ ~Aug 2021
Phase 2
Nov 2021
→ Mar 2028
Phase 2Current
NCT04088870
2,253 pts·SMA
2022-04→2028-03·Recruiting
NCT03351395
202 pts·SMA
2021-11→2026-09·Active
2,455 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-08-155mo awayConference· MCC
2026-09-246mo awayPh3 Readout· SMA
2028-03-192.0y awayPh3 Readout· SMA
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P2/3
Active
P2/3
Recruit…
Catalysts
Conference
2026-08-15 · 5mo away
MCC
Ph3 Readout
2026-09-24 · 6mo away
SMA
Ph3 Readout
2028-03-19 · 2.0y away
SMA
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04088870 | Phase 2/3 | SMA | Recruiting | 2253 | PFS |
| NCT03351395 | Phase 2/3 | SMA | Active | 202 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 |